SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. on January 10, 2023. The registrant is a Delaware corporation with principal executive offices in Westport, Connecticut, and its common stock trades on the NASDAQ Capital Market under the symbol BSGM.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a corporate event rather than periodic financial performance data.
Material Changes and Corporate Events
- Item 7.01 (Regulation FD Disclosure): On January 10, 2023, the Company announced that Bellin Health System in Green Bay, Wisconsin, has signed an agreement to acquire the Company's PURE EP® System.
- Item 9.01 (Exhibits): The filing includes a press release dated January 10, 2023, detailing the agreement.
Guidance, Outlook, and Risks
The Company explicitly states it undertakes no obligation to update, supplement, or amend the materials attached to this report. The filing notes that the information provided is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not intended to constitute a determination that the information is material or required by Regulation FD.
Investor Verification Checklist
- Verify the specific terms, valuation, and closing conditions of the agreement between BioSig Technologies and Bellin Health System regarding the PURE EP® System.
- Confirm the expected timeline for the transfer of the PURE EP® System and any associated revenue recognition impacts.
- Review the full text of the press release (Exhibit 99.1) for details not summarized in the 8-K body.
- Assess the strategic impact of this asset sale on the Company's future product pipeline and operational focus.